Delivery Order SPE2DB22D1002-SPE2DB25FLGE8
- Not listed
- The Defense Logistics Agency awarded a $2,145.94 delivery order to AmerisourceBergen Drug Corp on August 8, 2025, for the supply of NovoLog 100 Unit/ML vials (10 ML units). This is a firm fixed-price, non-set-aside contract with a completion date of August 11, 2025, and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. NovoLog is a rapid-acting insulin product used in diabetes management and represents a critical pharmaceutical commodity within the...
- The Defense Logistics Agency awarded a delivery order valued at $2,455.79 to AmerisourceBergen Drug Corp for NovoLog 100 Unit/mL vials (10mL) on August 1, 2025, with an ultimate completion date of August 4, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. NovoLog is a rapid-acting insulin product used in diabetes treatment and represents part of the agency's ongoing...
- The Defense Logistics Agency awarded a delivery order valued at $1,248.90 to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of NovoLog 100 Unit/mL vials (10 mL). This is a firm fixed price delivery order with no set-aside designation, utilizing competitive procurement procedures. The order is scheduled for completion by July 21, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. NovoLog is a rapid-acting insulin product...
- The Defense Logistics Agency awarded a $9,313.80 firm fixed-price delivery order to AmerisourceBergen Drug Corp for NovoLog 100 Unit/mL vials (10mL) on July 28, 2025, with completion targeted for July 29, 2025. The order will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. This contract was awarded on a competitive basis with no set-aside designation, reflecting AmerisourceBergen's established capability to meet federal pharmaceutical procurement...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 29, 2025, for the supply of NovoLog 100 unit/mL vials (10 mL) with a ceiling value of $3,162.88. This is a firm fixed price delivery order with no set-aside designation, indicating competitive award. The order is due for completion by July 30, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. NovoLog is a rapid-acting insulin used in diabetes...
- The Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a delivery order valued at $1,696.30 for NovoLog 100 Unit/ML vials (10 mL) on August 8, 2025, with an ultimate completion date of August 11, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at the company's corporate office location in Conshohocken, Pennsylvania. The contract represents a routine pharmaceutical procurement supporting federal medical...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for NovoLog 100 Unit/mL vials (10 mL) with a ceiling value of $1,361.43 under a firm fixed-price contract awarded on August 7, 2025. The delivery order, which is not set-aside, is scheduled for completion by August 8, 2025, with performance to be executed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. This order represents a routine pharmaceutical procurement for insulin supply to support...
- The Defense Logistics Agency awarded a $1,275.43 delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for the supply of NovoLog 100 Unit/mL vials (10 mL), an insulin product used in diabetes management. This firm fixed-price delivery order, with an ultimate completion date of August 13, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The award was made through open competition with no set-aside...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of NovoLog 100 Unit/mL Vial 10mL, an insulin medication used in diabetes management. This firm fixed price delivery order, valued at $2,624.10, was awarded on July 23, 2025, with an ultimate completion date of July 24, 2025. The contract was competitively awarded with no set-aside designation, and performance will be executed at the vendor's Corporate Office location in Conshohocken, Pennsylvania....
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for NovoLog 100 Unit/mL Vial 10mL insulin with a ceiling value of $8,157.52 under a firm fixed-price contract. This non-competitive delivery order was executed on July 28, 2025, with an ultimate completion date of July 29, 2025, and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's Indefinite Delivery Contract...
- SPE2DB22D1002Indefinite Delivery Contract
- SPE2DB22D1002-SPE2DB25FLGE8Delivery Order
The Defense Logistics Agency awarded a $9,344.14 delivery order to AmerisourceBergen Drug Corp for NovoLog 100 Unit/mL vials (10mL) with an ultimate completion date of August 13, 2025. This firm fixed-price contract was competitively awarded with no set-aside designation and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. NovoLog is a rapid-acting insulin used in diabetes management, representing part of the broader pharmaceutical supply chain supporting military and federal healthcare systems. This delivery order is issued under AmerisourceBergen Drug Corp's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.99 billion vehicle running through December 2026 that serves as a comprehensive global pharmaceutical support mechanism. As a major pharmaceutical distributor, AmerisourceBergen Drug Corp provides an extensive range of brand-name and generic medications, vaccines, and medical supplies to support military healthcare programs worldwide. The company's federal contract portfolio demonstrates its established capability to fulfill competitive federal medical procurement requirements across multiple therapeutic domains and customer bases, including the Defense Health Agency and U.S. Coast Guard.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $9.3k | 8/12/25 |